Surgical treatment of long-standing overt ventriculomegaly in adults (LOVA) by Ved, Ronak et al.
ORIGINAL ARTICLE - ABSTRACT
Surgical treatment of long-standing overt
ventriculomegaly in adults (LOVA)
Ronak Ved1 & Paul Leach1 & Chirag Patel1
Received: 28 July 2016 /Accepted: 13 October 2016 /Published online: 2 November 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background Longstanding overt ventriculomegaly in adults
(LOVA) is characterised by chronic hydrocephalus presumed
to begin during infancy, but arresting before becoming clini-
cally detectable. Later in life clinical features of hydrocepha-
lus ensue, typically in the 5th or 6th decades. Only a relatively
small number of LOVA case series have been published, and
ambiguity remains regarding optimal management. This case
series describes a series of patients with LOVA treated suc-
cessfully at a single neurosurgical institution using endoscopic
third ventriculostomy (ETV).
Methods A series of 14 patients were diagnosed with LOVA
using established clinical and radiological criteria. All patients
underwent an ETVand their clinical conditions were followed
up for up to 5 years post-operatively.
Results Fourteen patients (100 %) reported either improve-
ment or halt of progression in their presenting symptoms
3 months after ETV; 93 % of patients (n = 13) did not require
any further surgical intervention. One patient (7 %) reported
deterioration in symptoms beyond 3 months post-operatively,
which necessitated further surgery (ventriculoperitoneal
shunt). These promising outcomes after ETV are mirrored in
numerous other LOVA case series. Other works have analysed
the value of CSF shunting procedures in LOVA, with mixed
results. A direct, prospective comparison of outcomes after
shunt procedures and ETV, with a specific focus on LOVA
patients, is yet to be completed. A minority of patients fail to
respond, or develop recurrence of symptoms, months or years
after initial surgical intervention.
Conclusions ETVis an attractive option for surgical treatment
of LOVA. After surgical treatment for LOVA, long-term fol-
low-up should be considered to screen for late recurrence of
the condition.
Keywords Long-standing . Overt . Ventriculomegaly .
Adults . Hydrocephalus
Introduction
The term BLOVA^was first used by Oi and colleagues [1] to
define a cohort of adult patients with symptoms of chronic
hydrocephalus, a head circumference of more than 2 standard
deviations above the 98th percentile and overt tri-
ventriculomegaly on neuroimaging, in the absence of a sec-
ondary cause for aqueductal stenosis in adulthood. The mech-
anism for this phenomenon remains unclear [2]. It is
hypothesised that there is a full or partial obstruction of CSF
flow through the aqueduct of Sylvius before fusion of cranial
sutures (i.e. before age 24 months) followed by restoration of
CSF flow before clinical symptoms canmanifest in childhood.
This theory explains the large head circumference and initial
asymptomatic period of patients with true LOVA. This resto-
ration in CSF may be explained by re-establishment of flow
through the aqueduct, use of alternative flow pathways, mod-
ification of CSF production or a combination of these mech-
anisms [1, 3].
Later in adulthood, ill-defined alterations in CSF flow dy-
namics lead to a return of the previously arrested hydroceph-
alus and thus the gradual onset of symptoms of hydrocepha-
lus, such as headaches, cognitive decline4, imbalance, visual
problems and psychological disturbance [4]. Neuroimaging
typically reveals triventricular hydrocephalus with sparing of
the fourth ventricle and absence of aqueductal stenosis.
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Exemplar T2-weighted magnetic resonance images of a pa-
tient with LOVA are given in Fig. 1.
The process is typically slow and progressive in nature,
and a loss in brain parenchyma plasticity makes treatment
outcomes of LOVA difficult to predict. There are conflict-
ing case series describing outcomes for patients with
LOVA after neuroendoscopic and shunt-based CSF diver-
sion procedures, with each series advocating different
opinions as to the optimal management for this debilitating
condition.
This case series collates outcome data from LOVA patients
treated using endoscopic third ventriculostomy (ETV) at our
institution and reviews current data published about the pro-
posed pathophysiology, diagnosis, treatment options and pa-
tient outcomes for LOVA.
Methods
Fourteen patients were diagnosed with LOVA at a single neu-
rosurgical unit between 2011 and 2016, by virtue of all the
patients meeting the clinical and radiological criteria for
LOVA established by Oi et al. [2] (Table 1). All patients
underwent an ETV utilising the same standardised operative
technique, outlined by Al-Jumaily et al. [4]. A single burr hole
was performed in the midpupillary line just anterior to the
coronal suture. Disposable rigid endoscopes were used to cre-
ate a stoma in the floor of the third ventricle using a figure-of-
eight balloon. If present, any secondary membrane in the pre-
pontine cistern was opened.
Outcomes were assessed by clinical review of patients in
outpatient clinics (minimum 6 months, maximum 5 years)
post-operatively. If discharged from clinic, patients and their
primary care physicians were asked to contact the neurosurgi-
cal unit if symptoms recurred [6].
MEDLINE® database searches were conducted to retrieve
articles related to LOVA. Search terms included Blong-stand-
ing overt ventrioculomegaly in adults^, BLOVA^, Badult
hydrocephalus^, Badult ventriculomegaly^ and Barrested
hydrocephalus^. Two reviewers independently scrutinised
each retrieved article, evaluating the relevance of the study’s
sources and analysed the main findings of each study. A
Fig. 1 T2-weighted magnetic
resonance images from a patient
with LOVA: Case 14 in our case
series. a and b Sagittal slices
demonstrating
triventriculomegaly, with sparing
of the cerebral aqueduct and
fourth ventricle (thin white
arrows). There is apparent
enlargement of the sella turcica
due to the chronic nature of the
hydrocephalus (thick white
arrow). c Coronal slice
demonstrating obliteration of the
septum pellucidum (black arrow).
The triventriculomegaly can once
again be identified. d Subtle
sulcal effacement may be
appreciated, particularly in the
right temporo-parietal region, on
this axial slice from the same
scan. However, this patient’s age-
related (81) cerebral atrophy
renders this effacement less
marked than in typical cases of
LOVA (where presentation is in
the 5th–6th decades)
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summary of the results from the studies deemed relevant for
analysis is outlined in Table 2.
Results
Table 3 depicts the demographics, presenting symptoms and
outcomes for the 14 cases of LOVA treated at our institution
from 2011 to 2016. There were eight males and six females,
with a mean age of 51 (22–81). All 14 patients met the diag-
nostic criteria outlined in Table 1. All patients underwent ETV
in the first instance. Follow-up ranged from 6 to 60 months
(median 36 months). The mean head circumference was
58.2 cm.
One patient (7 %) experienced a post-operative complica-
tion after ETV in the form of a single tonic-clonic seizure
immediately post-operatively; there were no other complica-
tions post-ETV. All 14 patients (100 %) reported either im-
provement or halt of progression in their presenting symptoms
3 months after ETV; 93 % of patients (n = 13) did not require
any further surgical intervention. Only one patient (7 %) re-
ported deterioration in symptoms beyond 3 months that ne-
cessitated further surgery (VP shunt). Two patients have re-
cently reported minor headaches at 4 and 5 years follow-up
post-operatively and are awaiting review from the senior
author.
Discussion
Demographics
The clinical onset of LOVA can occur at any stage in adult-
hood, with a range between 22 and 81 years (median 54) in
our case series, which has been mirrored by others [4, 7, 8].
No clear-cut differences in patient sex have been identified
thus far. Some series have identified a trend towards sub-
normal IQ and cognitive abilities in LOVA patients, although
this feature does not appear to be universal across all cases of
LOVA [4, 7, 8]. Given the progressive nature of LOVA, early
identification of patients with potential symptoms and signs of
the condition is an attractive notion, as it may help to maxi-
mise the impact of any surgical intervention to implement it
earlier in the disease process. However, the subtle myriad of
early symptoms and the non-specific nature of large head cir-
cumference make early detection of LOVA a clinical
challenge.
Pathophysiology
The key features of LOVA are aqueductal stenosis, with arrest
of hydrocephalus before the onset of gross macrocephaly and
the symptoms of raised ICP. During the arrested hydrocephal-
ic period CSF flow is likely maintained via a combination of
rencannalisation of the aqueduct, utilisation of alternative CSF
flow routes, and modification of CSF production or absorp-
tion [1]. This asymptomatic interval is followed later in life by
a failure of the compensatory processes, leading to the symp-
tomatic phase of LOVA, which is typically progressive and
long term. Patients with an identifiable insult to alter CSF flow
are excluded from the definition of true LOVA, and the mech-
anisms that alter CSF dynamics to end the asymptomatic
phase of the condition remain unclear.
It is thought that the symptoms of LOVA develop as a
consequence of (1) failure of adequate CSF flow, (2) skull
base changes as a consequence of chronic and progressive rise
in ICP and (3) chronic pressure effects upon brain parenchyma
[1, 9, 10]. As such, early intervention has the potential to
modify the disease process before irreversible changes occur
as a result of chronically raised ICP [4].
Reports of persistent symptoms in patients with LOVA
after both ETVand shunt procedures have led to a theory that,
in some cases, the pathological process in adulthood leading
to CSF volume imbalance may actually take place more dis-
tally than the aqueduct; it may be a phenomenon of failure of
CSF re-absorption, thus unnameable to traditional CSF diver-
sion procedures. One case reported byRekate [13] illustrated a
LOVA patient whose symptoms remained refractory to CSF
shunt diversion and ETV, which in itself was complicated by
shunt infection. A venogram revealed bilateral transverse si-
nus stenosis, which was successfully treated utilising a neuro-
radiological venous-stenting procedure. The patient’s ICP
subsequently normalised. It is possible that back-pressure
from blockade of dural venous sinuses could instigate a chron-
ic, potentially reversible, aqueductal stenosis.
Symptomatology
Al-Jumaily et al. identified the most common features in
LOVA were headaches and imbalance [4], which were also
the most common presenting symptoms in our case series
(Table 3).
Table 1 Clinical and radiological criteria used to confirm the diagnosis
of LOVA in the presented case series (adapted from Oi et al., 2000 [1])
1. Clinical symptoms of hydrocephalus developing in adulthood—e.g.
headaches, cognitive decline, imbalance, gait disturbance,
psychological disturbance, visual deterioration/diplopia
2. Macrocephaly defined by head circumference >98th percentile in
adulthood (male 53.8 cm; female 52.9 cm) [5, 14]
3. Overt tri-ventriculomegaly (lateral and third ventricles) on
neuroimaging, with cortical sulcal effacement and/or destruction of
the sella turcica as evidence of long-standing ventriculomegaly
4. Absence of a secondary cause for aqueductal stenosis in adulthood
(e.g. previous meningitis, subarachnoid haemorrhage)
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The same group also highlighted that patients with LOVA
may demonstrate a myriad of cognitive and psychological
problems such as decline in memory, attention and language
skills, along with depression, anxiety and disinhibition [4, 7,
8]. Some case series have retrospectively identified that a pro-
portion of LOVA patients demonstrated sub-normal IQs or
evidence of early dementia before the onset of more overt
symptoms of raised ICP, such as headaches and gait distur-
bance [4, 7, 8]. However other patients demonstrate normal-
to-high IQs and report no evidence of hydrocephalic symp-
toms at childhood, with a large head circumference the only
pre-symptomatic indicator of a potential CSF flow problem
[3, 4]. Whether any pre-symptomatic decline in cognitive
function identified in a proportion of LOVA patients is a con-
sequence of the arrested hydrocephalus at childhood or wheth-
er it represents the earliest phase of the decompensation of
CSF flow in adulthood remains to be explored.
These symptoms may be difficult to identify clinically, as
the chronic nature of LOVA may permit some patients’ brains
undergo sufficient neuroplasticity to permit functional
reorganisation, minimising any clinical neuropsychological
deficits until late in the disease process [4, 8]. Nevertheless,
when cognitive decline, inattention and mood disturbances do
occur in LOVA, they can have significant impacts upon quality
of life [4]. These symptoms were marked in one case from the
cohort at our institution. In this case there was significant im-
provement in the social functioning, memory and mood after
ETV (Table 3). Whilst there are other reports of improvement
in these faculties after surgical treatment of LOVA [8], it is
thought that these symptoms are less likely to improve if treat-
ment is implemented late in the disease process [4].
Neuropsychological symptoms should therefore be assessed
and considered early in the therapeutic decision-making pro-
cess for LOVA patients who may appear to function highly
even after the point of clinical decompensation ensues [4, 6–8].
Treatment
All reviewed studies advocated surgery for symptomatic cases
of LOVA. However, the optimal CSF diversion procedure for
patients with LOVA has been debated for over a decade [1, 2,
9–12]. This debate has centred on a debate between
neuroendoscopic procedures versus CSF shunt diversion. Oi
et al. [1] reported outcomes for 18 patients with LOVA, 9
undergoing neuroendoscopic ETV (8) or aqueduct-plasty (1)
and 9 receiving ventriculoperitoneal (VP) shunts [7 differen-
tial pressure valve (DPV) shunts, 2 pressure programmable
valve (PPV) shunts]. All seven patients receiving DPV shunts
developed subdural haematomas, most likely as a conse-
quence of over-drainage. All of these patients required shunt
revision to a PPV shunt and/or ETV. Six of the nine patients
undergoing neuroendoscopic procedures developed radiolog-
ical and clinical arrest of hydrocephalus. Two patients in thisTa
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study suffered intra-axial haemorrhages after ETV. However,
subsequent series have demonstrated the relative safety of
ETV, with an overall complication risk of approximately
6 % [4, 13]. In one case series, a single ETV provided long-
term symptomatic relief for 88 % (21/24) of patients with
LOVA with no long-term complications port-operatively [6].
This correlates with our series, where there was only one
complication post ETV: a self-limiting generalised seizure
with no long-term sequelae for the patient. Conversely
100% (n = 14) of patients in our cohort reported improvement
or absence of progression in their symptoms at their first
follow-up appointment after ETV (3 months).
There are no case reports of significant change in ventric-
ular diameter after ETV or shunt insertion. The explanation
touted for this is that only a small volume of CSF needs to be
drained to achieve near-physiological ICP in adult hydroceph-
alus [11]. Improvements in radiological CSF flow and ICP
after ETV for LOVA have been identified [1, 13]. However,
these do not appear to correlate with clinical improvement,
and recurrence of symptoms does not reliably relate to failure
of flow through the ETV stoma [13]. It seems that after initial
drainage of CSF through the stoma, a more complicated
reorganisation of CSF dynamics takes place. Unpacking this
mechanism may then be the key to understanding how to
achieve sustained relief from the symptoms of LOVA.
The majority of studies, our series included, demonstrate
that a majority of LOVA patients can achieve post-operative
clinical improvement in headaches, balance, motor skills and
neuropsychological function after ETV [3, 4, 7, 8]. One large
retrospective study of ETV in adult patients (n = 163) recently
identified that the majority of patients undergoing primary
ETV (87 %; n = 130) reported subjective improvement in
symptoms 3 months post-operatively [3]. Only ten patients
(6 %) suffered post-operative complications. It should be not-
ed that the authors present data relating to their cohort as a
whole, which encompassed adult patients with normal pres-
sure hydrocephalus, partially treated childhood hydrocephalus
(i.e. failed VP shunt), hydrocephalus secondary to other intra-
cranial pathologies and LOVA. Separate outcome data for
these specific causes of adult hydrocephalus were not present-
ed; however, 97 patients in the whole cohort (60 %) did meet
the diagnostic criteria for LOVA, and their outcomes for ETV
success and complications align with data from other case
series specifically reviewing cases of LOVA (Table 2).
Despite these impressive outcomes after ETV, other works
report less promising results. In one series, six patients with
LOVA underwent ETV [10]. All six patients required a second-
ary procedure for persistent symptoms: shunt insertion, repeat
ETVor venous stenting. This small series highlighted the need
for continued follow-up whatever intervention is implemented,
as 50 % of patients (n = 3) suffered recurrence of symptoms at
18–36 months after their primary ETV, despite an initial im-
provement or arrest in progression of symptoms. Other studies
subsequently identified varying long-term success rates for
ETVs carried out for secondary hydrocephalus and LOVA,
with recurrence of symptoms occurring a number of months
or years post-operatively in a small proportion of patients in
some series [1, 4, 7–10]. Furthermore, studies have presented
patients in whom ETV did not facilitate objective improvement
in cognitive or neuropsychological tests, which may reflect the
progressive nature of the condition and inter-individual differ-
ences in neural compliance after a period of chronic hydroceph-
alus [4]. In patients with recurrent symptoms repeat ETV or
shunt insertion can sometimes deliver symptomatic improve-
ment, but this is again unpredictable. Thus, decisions to re-
operate need to be guided by individual patient circumstances.
Many cases of LOVA treated with ETV, including those in our
series, have demonstrated a benefit in the short-to-medium
term. However long-term follow-up, over a period of years,
should be considered, given the reports of recurrence and pro-
gression of symptoms in a minority of LOVA patients up to 2–
3 years post-operatively [4, 10, 13].
Two major advantages of ETV over traditional shunting
procedures are the high infection (and thus revision) rates
for shunt devices and the risk of shunt over-drainage and its
sequale in the latter. After the dramatic complications follow-
ing PPV insertion in the initial series by Oi et al., focus shifted
onto use of gravitational shunts for LOVA patients to mini-
mise the risk of over-drainage [1, 2, 11, 12]. In an important
study of shunt procedures for LOVA patients, 23 patients
elected gravitational shunt insertion after being offered the
choice of ETV or shunt insertion [11, 12]. Two patients
(9 %) developed small subdural haematomas, one of which
required drainage. Eighty-two percent (19) of the cohort dem-
onstrated clinical improvement after shunt insertion (follow-
up 6–75 months). The authors conclude that gravitational
shunts are a viable alternative to ETV in the management of
LOVA. However, it is of note that 15 % (4) of patients devel-
oped symptoms of overdrainge post-operatively, two of which
necessitated shunt revision surgery. Median follow-up was
29 months, which may not have been extensive enough to
capture cases of later shunt failure or infection in the cohort.
Furthermore, the work was limited by the non-randomised
methodology for the selection of patients for shunt insertion
and the institution’s relatively large, rigid endoscopes leading
to strict criteria for excluding ETV as a therapeutic option
(foramen of Munro width <6.5 mm and third ventricle floor
thickness >2.5 mm).
When discussing treatment options for LOVA, the signifi-
cant infection and revision rates associated with shunt proce-
dures, and the risks of under- or over-drainage, must be con-
sidered [4]. Conversely, the ventricular anatomy may not al-
ways be amenable to endoscopic CSF diversion procedures. A
comparative study between ETV and shunt implantation for
LOVA is yet to be completed; such work could provide useful
data to aid therapeutic decision-making for these patients.
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Conclusion
The mysterious pathophysiology underlying LOVA
makes therapeutic decision-making for these patients
complicated. Unchecked, its progressive nature can lead
to morbidity, with poor cognitive, psychological and
neurological outcomes [4].
It is vital that patients are counselled about the fact that
surgical intervention for LOVA does not bring with it a guar-
antee of long-term symptomatic relief or neuropsychological
improvement. The compliance of brain parenchyma is highly
variable between individuals and the capacity for recovery
after intervention does not appear to correlate with radiologi-
cal arrest of hydrocephalus [1, 11, 13].
However, the potential for slowing or halting progres-
sion via an established and safe procedure such as ETV
makes it an attractive therapeutic option for both clinician
and patient. ETVobviates many of the the risks associated
with CSF diversion implant procedures, but gravitational
shunts may be considered in cases unsuitable for ETV or
after recurrence of symptoms after initial ETV [2, 11, 12].
Such recurrence may occur months to years after initial
ETV. Long-term follow-up should be implemented after
surgery for LOVA.
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Comments
Any new and serious article on the LOVA condition is worthwhile as it
deals with a largely underestimated clinical problem. Therefore the ini-
tiative to edit a review on the respective literature as well as presenting
own experiences is valid. Only a few comments in order to intensify the
discussion should be allowed: it is important to broaden the definition the
LOVA condition in the sense that aqueductal stenosis or typical three-
ventricular hydrocephalus is a common, but not the only finding in these
patients. Many ventriculomegalic patients with cystic CSF spaces of the
posterior fossa (Blake’s pouch, Dandy-Walker variant, megacisterna
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magna, etc.) are found to develop typical LOVA symptoms, sometimes
already in early adulthood. Although some of the patients may have
limited relief from their symptoms after treatment, the long-term progno-
sis is frustrating for both patient and neurosurgeon and very much com-
parable to typical idiopathic NPH.
Therefore it must be strongly recommended to prevent this condition
by early detection and treatment of so-called asymptomatic or arrested
hydrocephalus during childhood.
Angela-Martina Messing-Junger
Bonn, Germany
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